UNAIDS DATA **2022** 188

THAILAND THAILAND

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2021
New HIV infections			
New HIV infections (all ages)	16 000	11 000	6500
	[15 000–16 000]	[10 000–11 000]	[6200–6800]
New HIV infections (0–14)	630	<200	<100
	[540–720]	[<100- <200]	[<100-<100]
New HIV infections (15-24)	7200	5600	3200
	[5100–8400]	[3900–6900]	[2200–4000]
New HIV infections (women, 15+)	4900	2700	1500
	[4500–5300]	[2500–2900]	[1400–1600]
New HIV infections (men, 15+)	10 000	8000	4900
	[9400– 1 1 000]	[7600–8500]	[4700–5200]
HIV incidence (all ages) per 1000 population	0.23 [0.22–0.24]	0.16 [0.15–0.17]	0.09 [0.09–0.10]
AIDS-related deaths			
AIDS-related deaths (all ages)	27 000	17 000	9300
	[22 000–32 000]	[14 000–22 000]	[7500–12 000]
AIDS-related deaths (0–14)	1200	<500	<100
	[1000–1300]	[<500- <500]	[<100- <200]
AIDS-related deaths (women, 15+)	9000	7400	4600
	[7000– 1 1 000]	[5800–9300]	[3400–6300]
AIDS-related deaths (men, 15+)	16 000	9700	4600
	[14 000–20 000]	[7900–12 000]	[3600–6300]
People living with HIV			
People living with HIV (all ages)	610 000	560 000	520 000
	[560 000–650 000]	[510 000–600 000]	[470 000–570 000]
People living with HIV (0–14)	11 000	5900	2000
	[9700–13 000]	[5000–6700]	[1700–2200]
eople living with HIV (women, 15+)	260 000	240 000	220 000
	[250 000–280 000]	[220 000–260 000]	[190 000–240 000]
People living with HIV (men, 15+)	330 000	310 000	300 000
	[310 000–360 000]	[280 000–330 000]	[270 000–330 000]
HIV prevalence (15–49)	1.5 [1.3–1.7]	1.3 [1.1–1.5]	1.0 [0.8–1.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts in private	No, laws penalizing consensual same-sex sexual acts have been decriminalized or have never existed anywhere in the country
Criminalization of possession of small amounts of drugs	Yes
Criminalization of transgender people	No
Laws or policies restricting the entry, stay and residence of people living with HIV	No restrictions
Parental consent for adolescents to access HIV testing	No
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATIO	N	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	2015	2019
(2019 refers to women only)	26.1	26.7
Percentage of people living with HIV who report experienced stigma and discrimination in the general community in the last 12 months		
Percentage of people living with HIV who report experiences of HIV-related		2022
discrimination in health-care settings		8.7
GENDER INEQUALITY AND VI	OLEN	CE
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		
Percentage of women and men aged 15 to 49 years who agree that a husband is justified in		2019
hitting or beating his wife for specific reasons		7.20


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


(Refers to women only)


Last available report: 2021 US\$ 2 047 770 US\$ 256 848 477 US\$ 11 382 023 US\$ 11 807 844 US\$ 3 984 694 US\$ 286 070 808

ASIA AND THE PACIFIC 189

EPIDEMIC TRANSITION METRICS







Change in new
HIV infections = -58%
since 2010

Change in AIDSrelated deaths = since 2010

Incidence: prevalence ratio (%)

= 1.3

Incidence: mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 91% or higher (the testing and treatment target for 2025).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					285 900
HIV prevalence	1.1%	11.9%		11%	0.7%
HIV testing and status awareness	57.0%	52.8%	38.1%	68.4%	
Antiretroviral therapy coverage	9.3%		43%		63.6%
Condom use	94.6%	77.8%	39.6%	78.8%	
Coverage of HIV prevention programmes	85.9%	49.5%		44.2%	
Avoidance of health care because of stigma and discrimination	5.1%	9.3%	4.7%		
Expenditures in US\$ (2021)	1 039 840	3 839 195	1 915 796	277 399	567 499

		IE5


Estimated number of incident tuberculosis cases among people living with HIV (2020) 9900 [7400 -13 000]

People living with HIV who started TB preventive therapy (2020)

Cervical cancer screening of women living with HIV

People coinfected with HIV and hepatitis C virus starting hepatitis C treatment

HIV TESTING AND TREATMENT CASCADE



All ages	94% [86–100%]	86% [78–94%]	84% [76–91%]
	490 362	447 061	433 774
Children (0-14)	75% [65–83%]	75% [65–83%]	66% [57–73%]
	1499	1499	1316
Women (15+)	94% [83–100%]	87% [77–95%]	84% [75–92%]
	204 724	188 615	183 526
Men (15+)	95% [86–100%]	86% [78–94%]	83% [76–91%]
	284 139	256 947	250 248

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load

0.1%

Knowledge of HIV prevention among young people aged 15–24 years

— Women

— Men

— Men

Condom use at last sex with a non-marital, non-cohabiting partner among people aged

–49 years (2017)	
— Women	

Women aged 15–49 years who have their demand for family planning satisfied by 75% 88%

95%

11

8.2%

76.8%

modern methods (2019)

Men aged 15–49 years who are circumcised

Not applicable

Voluntary medical male circumcisions

Not

People who received PrEP at least once during the reporting period (2021)

applicable

16 837

Harm reduction

 Use of sterile injecting equipment at last injection (2020)

Needles and syringes distributed per

- person who injects (2019)Coverage of agonist opioid methadone therapy (2021)
- Naloxone available (2022) Yes

CI IRAIRIA TI	VEDTICAL	TDANICMICCIONI	
	VERTICAL	. TRANSMISSION	
	V EIVII OF VE		

	2015	2021
Percentage of pregnant women living with HIV accessing antiretroviral medicines	95% [81–100%]	97% [81–100%]
Final vertical transmission rate including during breastfeeding	2.0% [1.9–2.1%]	1.6% [1.5–1.7%]
Early infant diagnosis	77.5% [67.5–91.4%]	92.2% [79.5– >95%]